The DOI matches its Crossref record; 261 of the 272 references it cites were found in a registry or an index; none of the 127 sources its claims cite is checked for support yet.
Mitochondrial DNA mutations and human disease
Open accessAbstract
Mitochondrial disorders are a group of clinically heterogeneous diseases, commonly defined by a lack of cellular energy due to oxidative phosphorylation (OXPHOS) defects. Since the identification of the first human pathological mitochondrial DNA (mtDNA) mutations in 1988, significant efforts have been spent in cataloguing the vast array of causative genetic defects of these disorders. Currently, more than 250 pathogenic mtDNA mutations have been identified. An ever-increasing number of nuclear DNA mutations are also being reported as the majority of proteins involved in mitochondrial metabolism and maintenance are nuclear-encoded. Understanding the phenotypic diversity and elucidating the molecular mechanisms at the basis of these diseases has however proved challenging. Progress has been hampered by the peculiar features of mitochondrial genetics, an inability to manipulate the mitochondrial genome, and difficulties in obtaining suitable models of disease. In this review, we will first outline the unique features of mitochondrial genetics before detailing the diseases and their genetic causes, focusing specifically on primary mtDNA genetic defects. The functional consequences of mtDNA mutations that have been characterised to date will also be discussed, along with current and potential future diagnostic and therapeutic advances.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
This review summarizes mitochondrial DNA (mtDNA) genetics, the clinical syndromes caused by primary mtDNA mutations, diagnostic approaches, experimental models, and therapeutic/prevention strategies. It emphasizes that more than 250 pathogenic mtDNA mutations are known, but heteroplasmy, threshold effects, genotype–phenotype heterogeneity, and limited disease models continue to complicate understanding and treatment.
Key findings
- Since the first pathogenic mtDNA mutations were identified in 1988, over 250 pathogenic mtDNA mutations have been characterized; the mtDNA mutation rate is 10- to 17-fold higher than nuclear DNA. Prevalence estimates from North East England suggest 1 in 10,000 people have clinically manifesting mtDNA disease and a further 1 in 6000 are at risk; mutation frequencies include 0.14% for m.3243A>G and ∼0.2% for m.1555A>G.
- Mitochondrial genetics is shaped by maternal inheritance, heteroplasmy/homoplasmy, a threshold effect typically around 60%–90% mutant mtDNA, mitotic segregation, clonal expansion, and a developmental bottleneck. Phenotype depends on mutation load and tissue, not simply on mutation size or location.
- Common syndromes and mutations include MELAS (over 80% have m.3243A>G), LHON (three primary mutations account for at least 95% of cases; 50% of males versus 10% of females develop visual loss; recovery is 71% with m.14484T>C versus 25% with m.11778G>A), NARP/MILS (m.8993T>G; mutant load greater than 95% associates with childhood MILS), MERRF (m.8344A>G), KSS/Pearson syndrome (single large-scale deletions), and CPEO.
- Diagnosis uses histochemistry (ragged red fibres, COX-deficient fibres), biochemical respiratory chain assays, and molecular testing (RFLP, long-range PCR, sequencing, microarrays). No effective treatment is currently available; exercise and gene therapy approaches are under investigation, and prevention strategies include prenatal diagnosis, preimplantation genetic diagnosis, pronuclear transfer, and spindle-chromosome transfer.
Methods
- Narrative review; no primary data, systematic search strategy, or formal inclusion criteria are described. The evidence base is published literature on mtDNA genetics, clinical syndromes, diagnosis, functional characterization, and management.
- The review synthesizes cited studies and databases, including MITOMAP, and discusses experimental models such as transmitochondrial cybrids, yeast models, and mouse models, as well as transcriptomic and proteomic investigations.
- Main analysis is qualitative synthesis, with figures for genotype–phenotype correlations and criteria for assigning pathogenicity to novel mtDNA variants.
Limitations
- The paper states that progress has been hampered by the peculiar features of mitochondrial genetics, an inability to manipulate the mitochondrial genome, and difficulties in obtaining suitable models of disease; it also notes that no effective therapies or cures are presently available and that exact prevalence is difficult to ascertain.
- The text makes evident that this is a narrative review without systematic search or primary data, and that several areas remain debated or uncertain, including the exact mechanism of mtDNA replication, the mtDNA bottleneck, and the mechanism of mtDNA deletion formation.
- Model-specific limitations are stated: cybrids often use aneuploid tumour cells and glycolytic host cells, and cybridization can alter the transcriptome; yeast are inherently homoplasmic and S. cerevisiae lack complex I; mouse mtDNA cannot be directly manipulated, requiring indirect approaches.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 of 127 cited sources checked · 0 supported · 0 flagged
None of the sources cited for this claim have been checked yet.
In the paper
“Although mtDNA repair systems do exist [51,52]”
§ Review Mitochondrial DNA mutations and human disease > 3. Clinical features of human mtDNA disease
What the sources say
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesThe paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The mitochondrial genome has a very high mutation rate, 10-to 17-fold higher than that observed in nuclear DNA.”
§ Review Mitochondrial DNA mutations and human disease > 3. Clinical features of human mtDNA disease
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIn the paper
“The occurrence of multiple mtDNA deletions of varying lengths in affected tissues may be due to inherited mutations in nuclear genes, whose products are involved in mtDNA maintenance and replication (e.g., POLG and PEO1 encoding Twinkle) and mitochondrial nucleotide metabolism (e.g., SLC25A4) [88][89][90].”
§ Review Mitochondrial DNA mutations and human disease > 3.2.2. MtDNA rearrangements
What the sources say
- Not checked yetcites [88][89][90]
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIn the paper
“To complicate matters further, a dominant mt-tRNA mutation, m.5545C N T in the MT-TW gene, was recently reported with levels of mutation at b25% in clinically affected tissues [83].”
§ Review Mitochondrial DNA mutations and human disease > 3.2.1. Point mutations
What the sources say
- Not checked yetcites [83] Sacconi, 2008, A functionally dominant mitochondrial DNA mutation, Hum. Mol. Genet. source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIn the paper
“The observation of a rapid segregation in mammalian heteroplasmic mtDNA genotypes between generations, with a return to homoplasmy in some progeny, has suggested the existence of a mtDNA bottleneck during development [67][68][69][70][71][72].”
§ Review Mitochondrial DNA mutations and human disease > 3.1.4. MtDNA bottleneck
What the sources say
- Not checked yetcites [67][68][69][70][71][72]
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIn the paper
“For example, an average annual 1% decrease in m.3243A N G mutation levels in blood has been described [63].”
§ Review Mitochondrial DNA mutations and human disease > 3.1.2. Mitotic segregation
What the sources say
- Not checked yetcites [63] Rahman, 2001, Decrease of 3243 A–>G mtDNA mutation from blood in MELAS syndrome: a longitudinal study, Am. J. Hum. Genet. source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesNone of the sources cited for this claim have been checked yet.
In the paper
“Over 80% of patients with MELAS have the m.3243A N G mutation in the MT-TL1 gene [109,110].”
§ Review Mitochondrial DNA mutations and human disease > 3.3.2.
What the sources say
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIn the paper
“In these children, there is a very high level of large-scale single mtDNA deletion present in all tissues [108].”
§ Review Mitochondrial DNA mutations and human disease > 3.3.1.4. Pearson syndrome.
What the sources say
- Not checked yetcites [108] Rotig, 1990, Pearson's marrow–pancreas syndrome. A multisystem mitochondrial disorder in infancy, J. Clin. Invest. source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesNone of the sources cited for this claim have been checked yet.
In the paper
“There are three primary LHON mtDNA mutations (m.11778G N A, m.3460G N A, and m.14484T N C), which in total are present in at least 95% of LHON cases [56,124].”
§ Review Mitochondrial DNA mutations and human disease > 3.3.2.4. Leber's hereditary optic neuropathy (LHON).
What the sources say
- Not checked yetcites [56] MITOMAP: A Human Mitochondrial Genome Database. http://www.mitomap.org. 2009.
- Not checked yetcites [124] Man, 2002, Leber hereditary optic neuropathy, J. Med. Genet. source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIn the paper
“It has subsequently been recognised that patients with a mutant load greater than 95% m.8993T N G have an onset in childhood with maternally inherited Leigh syndrome (MILS) [123].”
§ Review Mitochondrial DNA mutations and human disease > 3.3.2.3. Neuropathy, ataxia, and retinitis pigmentosa (NARP).
What the sources say
- Not checked yetcites [123] Tatuch, 1992, Heteroplasmic mtDNA mutation (T----G) at 8993 can cause Leigh disease when the percentage of abnormal mtDNA is high, Am. J. Hum. Genet.
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes
- Probably not a substantial claim. 6
- It may state two separate claims as one. 36
In the paper
“Currently, more than 250 pathogenic mtDNA mutations have been identified.”
- Also stated in: § 3. Clinical features of human mtDNA disease · plain
“Since then, over 250 pathogenic mtDNA mutations (point mutations and rearrangements) have been characterised [56]”
§ Review Mitochondrial DNA mutations and human disease > Abstract
What the sources say
- Not checked yetcites [56] MITOMAP: A Human Mitochondrial Genome Database. http://www.mitomap.org. 2009.
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Also stated in: § 3. Clinical features of human mtDNA disease · plain
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The onset of clinical symptoms, phenotypic variability, and variable penetrance of mitochondrial diseases are governed by a number of factors, including the threshold effect, mitotic segregation, clonal expansion, and a genetic bottleneck.”
§ Review Mitochondrial DNA mutations and human disease > 3.1. Specific features of mitochondrial disease
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
- Rests on an assumption: In heteroplasmy, the ratio of wild-type to mutant mtDNA determines the onset of clinical symptoms.
- Rests on an assumption: A minimum critical proportion of mutated mtDNAs is necessary before biochemical defects and tissue dysfunction become apparent.
- Rests on an assumption: The threshold level varies for each mutation and differs amongst tissues, being lower in tissues highly dependent on OXPHOS metabolism than in tissues that can rely on anaerobic glycolysis.
- Rests on an assumption: Typically, the threshold value is in the range of 60%-90% mutant to wild-type mtDNA.
- Rests on an assumption: During mitosis, mitochondria are randomly segregated, and in heteroplasmic cells, the proportion of mutant mtDNA in the daughter cells can shift.
- Rests on an assumption: If the mutant load exceeds the pathogenic threshold for that tissue, clinical expression of the disease can occur.
- Rests on an assumption: Mutant mtDNA may be lost, particularly in fast-dividing tissues.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“they are not sufficient to counteract the oxidative damage sustained by the mitochondrial genome due to its proximity to the RC complexes in the IMM and the ROS they generate.Protective histones are also lacking.”
§ Review Mitochondrial DNA mutations and human disease > 3. Clinical features of human mtDNA disease
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Although the threshold level can partly explain the disease phenotypes observed in patients, an exact correlation between clinical severity and the proportion of mtDNA mutation is lacking [62].”
§ Review Mitochondrial DNA mutations and human disease > 3.1.1. Threshold effect
What the sources say
- Not checked yetcites [62] Wong, 2007, Diagnostic challenges of mitochondrial DNA disorders, Mitochondrion source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: In heteroplasmy, the ratio of wild-type to mutant mtDNA determines the onset of clinical symptoms.
- Rests on an assumption: A minimum critical proportion of mutated mtDNAs is necessary before biochemical defects and tissue dysfunction become apparent.
- Rests on an assumption: The threshold level varies for each mutation and differs amongst tissues, being lower in tissues highly dependent on OXPHOS metabolism than in tissues that can rely on anaerobic glycolysis.
- Rests on an assumption: Typically, the threshold value is in the range of 60%-90% mutant to wild-type mtDNA.
None of the sources cited for this claim have been checked yet.
In the paper
“Clonal expansion refers to the preferential amplification of mtDNA mutations to a high level in post-mitotic tissues [64,65].”
§ Review Mitochondrial DNA mutations and human disease > 3.1.3. Clonal expansion
What the sources say
- Not checked yetcites [64] Larsson, 1990, Progressive increase of the mutated mitochondrial DNA fraction in Kearns–Sayre syndrome, Pediatr. Res. source
- Not checked yetcites [65] Weber, 1997, A new mtDNA mutation showing accumulation with time and restriction to skeletal muscle, Am. J. Hum. Genet.
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“CPEO is typically caused by sporadic large-scale single deletions or multiple mtDNA deletions [119,120], although mtDNA point mutations are detected in some patients (e.g., m.3243A N G [121], m.12316G N A [122]).”
§ Review Mitochondrial DNA mutations and human disease > 3.3.2.2. Chronic progressive external ophthalmoplegia (CPEO).
What the sources say
- Not checked yetcites [119] Moraes, 1989, Mitochondrial DNA deletions in progressive external ophthalmoplegia and Kearns–Sayre syndrome, N. Engl. J. Med. source
- Not checked yetcites [120] Van Goethem, 2003, Progressive external ophthalmoplegia characterized by multiple deletions of mitochondrial DNA: unraveling the pathogenesis of human mitochondrial DNA instability and the initiation of a genetic classification, Neuromol. Med. source
- Not checked yetcites [121] Moraes, 1993, Atypical clinical presentations associated with the MELAS mutation at position 3243 of human mitochondrial DNA, Neuromuscul. Disord. source
- Not checked yetcites [122] Cardaioli, 2008, Chronic progressive external ophthalmoplegia: a new heteroplasmic tRNA(Leu(CUN)) mutation of mitochondrial DNA, J. Neurol. Sci. source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Single mtDNA deletions occur sporadically early in development, and the identical deletion is present in all cells within affected tissues [87].”
§ Review Mitochondrial DNA mutations and human disease > 3.2.2. MtDNA rearrangements
What the sources say
- Not checked yetcites [87] Chen, 1995, Rearranged mitochondrial genomes are present in human oocytes, Am. J. Hum. Genet.
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Leigh syndrome is due to severe failure of oxidative metabolism and can be due to a variety of different genetic defects affecting either the mitochondrial (e.g., m.8993T N C/G, m.10158T N C, m.10191T N C) or nuclear genome (e.g., SURF1 gene) [105].”
§ Review Mitochondrial DNA mutations and human disease > 3.3.1. Mitochondrial diseases with onset in early infancy/childhood 3.3.1.1. Leigh syndrome.
What the sources say
- Not checked yetcites [105] Finsterer, 2008, Leigh and Leigh-like syndrome in children and adults, Pediatr. Neurol. source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“They mainly occur between the origins of replication, O H and O L , and are typically flanked by short direct repeats [94,95].”
§ Review Mitochondrial DNA mutations and human disease > 3.2.2. MtDNA rearrangements
What the sources say
- Not checked yetcites [94] Bua, 2006, Mitochondrial DNA-deletion mutations accumulate intracellularly to detrimental levels in aged human skeletal muscle fibers, Am. J. Hum. Genet. source
- Not checked yetcites [95] Samuels, 2004, Two direct repeats cause most human mtDNA deletions, Trends Genet. source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“The majority of mtDNA rearrangement mutations are large-scale deletions, which vary in size from 1.3 to 8 kb and span several genes [86].”
§ Review Mitochondrial DNA mutations and human disease > 3.2.2. MtDNA rearrangements
What the sources say
- Not checked yetcites [86] Schon, 1989, A direct repeat is a hotspot for large-scale deletion of human mitochondrial DNA, Science source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Whilst cybrids and yeast have helped to further our current understanding of mitochondrial genetics and the molecular mechanisms of disease, a mammalian in vivo model system is ultimately necessary for answering the many questions regarding mtDNA biology, mitochondrial disease pathogenesis and tissue specificity that still remain.”
§ Review Mitochondrial DNA mutations and human disease > 5.1.3. Mouse models
Tests✓ Asserted: passes✗ Checkable: fails✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may be too vague to check against evidence.
None of the sources cited for this claim have been checked yet.
In the paper
“In addition, these cell models have challenged our established criteria for pathogenicity with the identification of the first mt-tRNA suppressor mutation, m.12300G N A in MT-L2 [154], and the first functionally dominant mt-tRNA mutation, m.5545C N T in MT-TW [155].”
§ Review Mitochondrial DNA mutations and human disease > 5.1.1. Transmitochondrial cybrids
What the sources say
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“A global decrease in the activity of COX is usually suggestive of a nuclear mutation in an ancillary protein required for COX assembly such as SURF1 but can be associated with some homoplasmic mt-tRNA defects [77,78].”
§ Review Mitochondrial DNA mutations and human disease > 4.1. Histochemical and biochemical testing
What the sources say
- Not checked yetcites [77] McFarland, 2002, Multiple neonatal deaths due to a homoplasmic mitochondrial DNA mutation, Nat. Genet. source
- Not checked yetcites [78] Taylor, 2003, A homoplasmic mitochondrial transfer ribonucleic acid mutation as a cause of maternally inherited hypertrophic cardiomyopathy, J. Am. Coll. Cardiol. source
Strength:hedged· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“The assessment of m.3243A N G mutation load in urinary sediments not only provides a correlate with the level in muscle but also has proven to be an accurate indicator of clinical outcome for these patients [138].”
§ Review Mitochondrial DNA mutations and human disease > 4.2. Molecular genetic testing
What the sources say
- Not checked yetcites [138] Whittaker, 2009, Urine heteroplasmy is the best predictor of clinical outcome in the m.3243A>G mtDNA mutation, Neurology source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“By allowing selected mtDNA sequences to be expressed against fixed nuclear backgrounds, not only can cybrids be employed for establishing and/or confirming the genetic origin of a mitochondrial disorder, but they can also provide a controlled environment in which to study both the functional and physiological consequences of varying levels of heteroplasmy of specific mtDNA mutations as well as the”
§ Review Mitochondrial DNA mutations and human disease > 5.1.1. Transmitochondrial cybrids
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Consequently, it is unlikely that a reduced respiration rate is solely responsible for this variability, but rather additional molecular mechanisms must also contribute to the development and clinical presentation of disease.”
§ Review Mitochondrial DNA mutations and human disease > 5. Functional characterisation of mtDNA mutations
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: Clinical phenotypes of mitochondrial disorders are extremely heterogeneous.
- Rests on an assumption: Pathogenic mtDNA mutations invariably result in a general defect in mitochondrial respiration that leads to a reduced ability to produce cellular ATP.
In the paper
“Most importantly, this can be achieved in a highly controlled fashion as DNA delivered to mitochondria via biolistic transformation can only incorporate into the mitochondrial genome by homologous recombination [160].”
§ Review Mitochondrial DNA mutations and human disease > 5.1.2. Yeast models
What the sources say
- Not checked yetcites [160] Bonnefoy, 2001, Genetic transformation of Saccharomyces cerevisiae mitochondria, Methods Cell Biol. source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“However, the introduction over the past decade of an alternative model, the obligate aerobic yeast Yarrowia lipolytica, which possesses a vital proton-pumping NADH:ubiquinone oxidoreductase, has enabled important structural and functional analyses of mitochondrial complex I [168].”
§ Review Mitochondrial DNA mutations and human disease > 5.1.2. Yeast models
What the sources say
- Not checked yetcites [168] Kerscher, 2004, Application of the yeast Yarrowia lipolytica as a model to analyse human pathogenic mutations in mitochondrial complex I (NADH:ubiquinone oxidoreductase), Biochim. Biophys. Acta source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Additional transmitochondrial mouse models, showing signs of mitochondrial dysfunction and capable of transmitting mtDNA mutations to subsequent generations, have since been established, including the 'Mito-mice' model that harbours high levels of a single heteroplasmic mtDNA deletion and shows a multitude of symptoms including myopathy, cardiomyopathy, renal failure, anaemia, deafness, lactic”
§ Review Mitochondrial DNA mutations and human disease > 5.1.3. Mouse models
What the sources say
- Not checked yetcites [172] Inoue, 2000, Generation of mice with mitochondrial dysfunction by introducing mouse mtDNA carrying a deletion into zygotes, Nat. Genet. source
- Not checked yetcites [173] Nakada, 2004, Accumulation of pathogenic DeltamtDNA induced deafness but not diabetic phenotypes in mito-mice, Biochem. Biophys. Res. Commun. source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Also, S. cerevisiae are inherently homoplasmic, thus precluding threshold studies, although it is possible to modulate the severity of yeast respiratory phenotypes by studying mt-tRNA mutations in different nuclear contexts [163,164].”
§ Review Mitochondrial DNA mutations and human disease > 5.1.2. Yeast models
What the sources say
- Not checked yetcites [163] De Luca, 2006, Mutations in yeast mt tRNAs: specific and general suppression by nuclear encoded tRNA interactors, Gene source
- Not checked yetcites [164] Montanari, 2008, Yeast as a model of human mitochondrial tRNA base substitutions: investigation of the molecular basis of respiratory defects, Rna source
Strength:hedged· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“The progression of the disease seems to depend upon the responsible mutation with 71% of patients with the m.14484T N C mutation showing some recovery, compared to 25% with m.11778G N A [125].”
§ Review Mitochondrial DNA mutations and human disease > 3.3.2.4. Leber's hereditary optic neuropathy (LHON).
What the sources say
- Not checked yetcites [125] Riordan-Eva, 1995, The clinical features of Leber's hereditary optic neuropathy defined by the presence of a pathogenic mitochondrial DNA mutation, Brain source
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“For example, cybrids harbouring the homoplasmic MT-TV m.1624C N T mutation, which caused a profound metabolic defect in skeletal and cardiac muscle, with low complex I and IV activities, and resulted in multiple neonatal deaths [159], were found to lack the marked respiratory defect despite retaining a striking reduction in mt-tRNA Val steady-state levels [159].”
§ Review Mitochondrial DNA mutations and human disease > 5.1.1. Transmitochondrial cybrids
What the sources say
- Not checked yetcites [159] Rorbach, 2008, Overexpression of human mitochondrial valyl tRNA synthetase can partially restore levels of cognate mt-tRNAVal carrying the pathogenic C25U mutation, Nucleic Acids Res. source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Increased ROS production has been described in neuronal NT2 cybrid cells containing m.3460G N A and m.11778G N A LHON mutations [187], in lymphocytes with m.8993T N C and m.8993T N G NARP mutations [188] and more recently in the chimeric m.3243A N G mice mentioned previously [175].”
§ Review Mitochondrial DNA mutations and human disease > 5.2. Molecular mechanisms of mitochondrial disease
What the sources say
- Not checked yetcites [187] Wong, 2002, Differentiation-specific effects of LHON mutations introduced into neuronal NT2 cells, Hum. Mol. Genet. source
- Not checked yetcites [188] Baracca, 2007, Biochemical phenotypes associated with the mitochondrial ATP6 gene mutations at nt8993, Biochim. Biophys. Acta source
- Not checked yetcites [175] Li, 2008, Increased ROS generation and SOD activity in heteroplasmic tissues of transmitochondrial mice with A3243G mitochondrial DNA mutation, Genet. Mol. Res. source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Conversely, normal levels of ROS were measured in the POLG1 mutator mice, which eventually accumulate sufficient mtDNA mutations to cause severe OXPHOS deficiency [189].”
§ Review Mitochondrial DNA mutations and human disease > 5.2. Molecular mechanisms of mitochondrial disease
What the sources say
- Not checked yetcites [189] Trifunovic, 2005, Somatic mtDNA mutations cause aging phenotypes without affecting reactive oxygen species production, Proc. Natl. Acad. Sci. U. S. A. source
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Biochemical effects of mtDNA mutations have been well described in all experimental systems and are invariably characterised by lower cellular respiration, compromised RC complex activity, and reduced ATP synthesis.”
§ Review Mitochondrial DNA mutations and human disease > 5.2. Molecular mechanisms of mitochondrial disease
Strength:boosted· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear? Based: unclearIt may state two separate claims as one.
In the paper
“and the mt-tRNA Tyr m.5874T N C and m.5877C N T transitions [204].”
§ Review Mitochondrial DNA mutations and human disease > 5.2.1. Molecular impacts of mt-tRNA mutations
What the sources say
- Not checked yetcites [204] Bonnefond, 2008, Decreased aminoacylation in pathology-related mutants of mitochondrial tRNATyr is associated with structural perturbations in tRNA architecture, RNA source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Furthermore, no increase in programmed cell death was identified in this mouse model, contrary to a double TFAM knockout mouse model in which substantial apoptosis occurred at embryonic day 9.5 [179,190].”
§ Review Mitochondrial DNA mutations and human disease > 5.2. Molecular mechanisms of mitochondrial disease
What the sources say
- Not checked yetcites [179] Wang, 1999, Dilated cardiomyopathy and atrioventricular conduction blocks induced by heart-specific inactivation of mitochondrial DNA gene expression, Nat. Genet. source
- Not checked yetcites [190] Wang, 2001, Increased in vivo apoptosis in cells lacking mitochondrial DNA gene expression, Proc. Natl. Acad. Sci. U. S. A. source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“However, although PNAs colocalised to mitochondria in intact cells, they were not able to cross the IMM.”
§ Review Mitochondrial DNA mutations and human disease > 6.2. Gene therapy
What the sources say
- Not checked yetcites [234] Taylor, 1997, Selective inhibition of mutant human mitochondrial DNA replication in vitro by peptide nucleic acids, Nat. Genet. source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Other shared transcriptional consequences of mitochondrial dysfunction include inhibition of both ubiquitin-mediated protein degradation and mitochondrial and nuclear ribosomal protein synthesis [214,215], as well as activation of the unfolded protein response [215,216].”
§ Review Mitochondrial DNA mutations and human disease > 5.2.2. Global effects of mtDNA mutations
What the sources say
- Not checked yetcites [214] Jahangir Tafrechi, 2005, Distinct nuclear gene expression profiles in cells with mtDNA depletion and homoplasmic A3243G mutation, Mutat. Res. source
- Not checked yetcites [215] Alemi, 2007, Mitochondrial DNA deletions inhibit proteasomal activity and stimulate an autophagic transcript, Free Radic. Biol. Med. source
- Not checked yetcites [216] Cortopassi, 2006, Mitochondrial disease activates transcripts of the unfolded protein response and cell cycle and inhibits vesicular secretion and oligodendrocyte-specific transcripts, Mitochondrion source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Moreover, the nature of the mtDNA mutations, in particular the m.9205delTA deletion, which eliminates the MT-ATP6 gene stop codon, placing MT-CO3 immediately in frame, and causes a marked decrease in RNA14 (MT-ATP8 and -6-encoding bicistronic transcript) steady-state levels [81]”
§ Review Mitochondrial DNA mutations and human disease > 5.2.2. Global effects of mtDNA mutations
What the sources say
- Not checked yetcites [81] Temperley, 2003, Investigation of a pathogenic mtDNA microdeletion reveals a translation-dependent deadenylation decay pathway in human mitochondria, Hum. Mol. Genet. source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Muscle conditioning enhanced ATP levels, delayed disease onset, and increased life expectancy in these mice.”
§ Review Mitochondrial DNA mutations and human disease > 6.1. Exercise therapy
What the sources say
- Not checked yetcites [231] Wenz, 2009, Endurance exercise is protective for mice with mitochondrial myopathy, J. Appl. Physiol. source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Well tolerated and safe, endurance training for up to 14 weeks has been found to improve OXPHOS function, although no concomitant shift in mutated mtDNA levels in muscle has been observed and cessation in training does cause a loss of the physiological adaptations [228][229][230].”
§ Review Mitochondrial DNA mutations and human disease > 6.1. Exercise therapy
What the sources say
- Not checked yetcites [228] Taivassalo, 2005, Exercise and training in mitochondrial myopathies, Med. Sci. Sports Exerc. source
- Not checked yetcites [229] Jeppesen, 2006, Aerobic training is safe and improves exercise capacity in patients with mitochondrial myopathy, Brain source
- Not checked yetcites [230] Taivassalo, 2006, Endurance training and detraining in mitochondrial myopathies due to single large-scale mtDNA deletions, Brain source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Imported tRNA Lys molecules are correctly aminoacylated, able to participate in mitochondrial translation, and partially rescue mitochondrial functions [242].”
§ Review Mitochondrial DNA mutations and human disease > 6.2. Gene therapy
What the sources say
- Not checked yetcites [242] Kolesnikova, 2004, Nuclear DNA-encoded tRNAs targeted into mitochondria can rescue a mitochondrial DNA mutation associated with the MERRF syndrome in cultured human cells, Hum. Mol. Genet. source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“The most recent mammalian mitochondrial compendium (MitoCarta) consists of 1098 identified proteins [209].”
§ Review Mitochondrial DNA mutations and human disease > 5.2.2. Global effects of mtDNA mutations
What the sources say
- Not checked yetcites [209] Pagliarini, 2008, A mitochondrial protein compendium elucidates complex I disease biology, Cell source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“Furthermore, two recent studies have demonstrated an increase in mutant mt-tRNA Val [159] and mt-tRNA Leu(UUR) [166] steady-state levels following overexpression of the valyl and leucyl synthetases, respectively.”
§ Review Mitochondrial DNA mutations and human disease > 6.2. Gene therapy
What the sources say
- Not checked yetcites [159] Rorbach, 2008, Overexpression of human mitochondrial valyl tRNA synthetase can partially restore levels of cognate mt-tRNAVal carrying the pathogenic C25U mutation, Nucleic Acids Res. source
- Not checked yetcites [166] Park, 2008, Overexpressed mitochondrial leucyl-tRNA synthetase suppresses the A3243G mutation in the mitochondrial tRNA(Leu(UUR)) gene, Rna source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Twelve-week resistance training studies in patients with single, large-scale mtDNA deletions have been demonstrated to increase satellite cell number with concomitant improvements in muscular strength and oxidative capacity evidenced by a decrease in the proportion of COX-negative fibres [233].”
§ Review Mitochondrial DNA mutations and human disease > 6.1. Exercise therapy
What the sources say
- Not checked yetcites [233] Murphy, 2008, Resistance training in patients with single, large-scale deletions of mitochondrial DNA, Brain source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Indeed, AOX was well tolerated and transfectants displayed remarkable levels of cyanide resistance to mitochondrial metabolite oxidation.”
§ Review Mitochondrial DNA mutations and human disease > 6.2. Gene therapy
What the sources say
- Not checked yetcites [247] Hakkaart, 2006, Allotopic expression of a mitochondrial alternative oxidase confers cyanide resistance to human cell respiration, EMBO Rep. source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“However, studies in heteroplasmic mice have demonstrated almost identical levels of heteroplasmy between the ooplasm and polar body of the mature oocyte and also between individual blastomeres [250].”
§ Review Mitochondrial DNA mutations and human disease > 6.3. Prevention of mtDNA disease transmission
What the sources say
- Not checked yetcites [250] Dean, 2003, Prospect of preimplantation genetic diagnosis for heritable mitochondrial DNA diseases, Mol. Hum. Reprod. source
Load-bearingStrength:boosted· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“An alternative approach involving pronuclear transfer, the transfer of the pronuclei from a fertilised zygote of a mother with mtDNA disease to an enucleated zygote from a healthy donor female, is presently being investigated in abnormally fertilised human embryos (Turnbull et al., unpublished data).”
§ Review Mitochondrial DNA mutations and human disease > 6.3. Prevention of mtDNA disease transmission
What the sources say
- Not checked yetcites Turnbull et al., unpublished data
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Recently, spindle-chromosome complex transfer from a mature primate oocyte to an enucleated primate egg successfully produced healthy offspring, in which, importantly, spindle donor mtDNA was not detected [252].”
§ Review Mitochondrial DNA mutations and human disease > 6.3. Prevention of mtDNA disease transmission
What the sources say
- Not checked yetcites [252] Tachibana, 2009, Mitochondrial gene replacement in primate offspring and embryonic stem cells, Nature source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Furthermore, an encouraging strategy for the potential rescue of mitochondrial COX defects may soon be possible following the successful transfection and IMM targeting in human cultured cells of the sea squirt Ciona intestinalis cyanide-insensitive alternative oxidase (AOX) [247].”
§ Review Mitochondrial DNA mutations and human disease > 6.2. Gene therapy
What the sources say
- Not checked yetcites [247] Hakkaart, 2006, Allotopic expression of a mitochondrial alternative oxidase confers cyanide resistance to human cell respiration, EMBO Rep. source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Similarly, xenotopic expression of the green alga Chlamydomonas reinhardtii ATPase 6 (CrATP6) in human cybrid cells harbouring the m.8993T N G mutation resulted in moderately improved ATP production whilst cellular viability was fully recovered [246].”
§ Review Mitochondrial DNA mutations and human disease > 6.2. Gene therapy
What the sources say
- Not checked yetcites [246] Ojaimi, 2002, An algal nucleus-encoded subunit of mitochondrial ATP synthase rescues a defect in the analogous human mitochondrial-encoded subunit, Mol. Biol. Cell source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper relies on this without support.
In heteroplasmy, the ratio of wild-type to mutant mtDNA determines the onset of clinical symptoms.
“In the presence of heteroplasmy, the ratio of wild-type to mutant mtDNA determines the onset of clinical symptoms.”
The paper relies on this without support.
A minimum critical proportion of mutated mtDNAs is necessary before biochemical defects and tissue dysfunction become apparent.
“A minimum critical proportion of mutated mtDNAs is necessary before biochemical defects and tissue dysfunction become apparent.”
The paper relies on this without support.
The threshold level varies for each mutation and differs amongst tissues, being lower in tissues highly dependent on OXPHOS metabolism than in tissues that can rely on anaerobic glycolysis.
“This threshold level varies for each mutation and differs amongst tissues, being lower in tissues highly dependent on OXPHOS metabolism than in tissues that can rely on anaerobic glycolysis.”
The paper relies on this without support.
Typically, the threshold value is in the range of 60%-90% mutant to wild-type mtDNA.
“Typically, the threshold value is in the range of 60%-90% mutant to wild-type mtDNA.”
The paper relies on this without support.
During mitosis, mitochondria are randomly segregated, and in heteroplasmic cells, the proportion of mutant mtDNA in the daughter cells can shift.
“During mitosis, mitochondria are randomly segregated, and in heteroplasmic cells, the proportion of mutant mtDNA in the daughter cells can thus shift.”
The paper relies on this without support.
If the mutant load exceeds the pathogenic threshold for that tissue, clinical expression of the disease can occur.
“Should the mutant load exceed the pathogenic threshold for that tissue, clinical expression of the disease can occur.”
The paper relies on this without support.
Mutant mtDNA may be lost, particularly in fast-dividing tissues.
“Conversely, mutant mtDNA may be lost, particularly in fast-dividing tissues.”
The paper relies on this without support.
MtDNA point mutations are usually maternally inherited.
“MtDNA point mutations are usually maternally inherited.”
The paper relies on this without support.
More than half of disease-related point mutations reported are located within mt-tRNA genes.
“However, more than half of disease-related point mutations reported are located within mt-tRNA genes.”
The paper relies on this without support.
Point mutations in mitochondrial protein-coding genes specifically affect the function of the RC complex to which the corresponding protein belongs, whereas mt-tRNA mutations may impair overall mitochondrial translation by reducing the availability of functional mt-tRNAs.
“Phenotypically, point mutations in mitochondrial protein-coding genes specifically affect the function of the RC complex to which the corresponding protein belongs, whereas mt-tRNA mutations may impair overall mitochondrial translation by reducing the availability of functional mt-tRNAs.”
The paper relies on this without support.
Point mutations are mostly heteroplasmic, displaying considerable clinical heterogeneity, and are considered highly recessive.
“Point mutations are mostly heteroplasmic, displaying considerable clinical heterogeneity, and are considered highly recessive.”
The paper relies on this without support.
LHON is usually due to a homoplasmic mtDNA mutation and all maternal offspring will inherit the mutation; however, whilst 50% of males will be affected, only 10% of females will develop visual loss.
“LHON is usually due to a homoplasmic mtDNA mutation and all maternal offspring will inherit the mutation; however, whilst 50% of males will be affected, only 10% of females will develop visual loss.”
The paper relies on this without support.
The clinical syndromes associated with mtDNA mutations are extremely variable and patients can present at any stage in life.
“The clinical syndromes associated with mtDNA mutations are extremely variable and patients can present at any stage in life.”
The paper relies on this without support.
On the whole, the age of onset reflects the level of mutation and the severity of the biochemical defect, but other factors (presumably nuclear genetic or environmental) also affect the expression of disease.
“On the whole, the age of onset reflects the level of mutation and the severity of the biochemical defect, but other factors (presumably nuclear genetic or environmental) also effect the expression of disease.”
The paper relies on this without support.
Many, but not all, patients with mtDNA disease show histological and histochemical changes in affected tissue, indicative of RC dysfunction.
“Many, but not all, patients with mtDNA disease show histological and histochemical changes in affected tissue, indicative of RC dysfunction.”
The paper relies on this without support.
Some mutations—mtDNA rearrangements and certain mtDNA point mutations—are only present in clinically affected tissues, necessitating the work-up on postmitotic (muscle) DNA samples.
“Some mutations-mtDNA rearrangements and certain mtDNA point mutations-are only present in clinically affected tissues, necessitating the work-up on postmitotic (muscle) DNA samples.”
The paper relies on this without support.
Due to its small size, screening the entire mitochondrial genome can be undertaken relatively easily to identify rare or novel mtDNA mutations in patients with suspected mtDNA disease.
“Due to its small size, screening the entire mitochondrial genome can be undertaken relatively easily to identify rare or novel mtDNA mutations in patients with suspected mtDNA disease.”
The paper relies on this without support.
Clinical phenotypes of mitochondrial disorders are extremely heterogeneous.
“The clinical phenotypes of mitochondrial disorders are however extremely heterogeneous.”
The paper relies on this without support.
Engineering mtDNA is problematic due to its polyploidy, inaccessibility within a double-membraned organelle, and apparent lack of, or minimal, recombination, which have prevented the successful transfection of autonomously replicating foreign DNA plasmids or modified mtDNA into mitochondria to date.
“Firstly, engineering mtDNA is problematic due to its polyploidy, inaccessibility within a double-membraned organelle, and apparent lack of, or minimal, recombination, which have prevented the successful transfection of autonomously replicating foreign DNA plasmids or modified mtDNA into mitochondria to date.”
The paper relies on this without support.
Most cybrid models are generated using aneuploid tumour cells.
“Most cybrid models are generated using aneuploid tumour cells.”
The authors state this as an assumption.
Aneuploidy can affect the stoichiometry of nuclear- and mitochondrial-encoded RC subunits, thus interfering with genotype-phenotype relationships.
“however, it is reasonable to assume that it can affect the stoichiometry of nuclear-and mitochondrial-encoded RC subunits, thus interfering with genotype-phenotype relationships.”
The paper relies on this without support.
Tumour cells are largely glycolysis-dependent, relying little on OXPHOS for generating the majority of their energy requirements.
“On a similar note, tumour cells are largely glycolysis-dependent, relying little on OXPHOS for generating the majority of their energy requirements.”
The paper relies on this without support.
mtDNA disorders typically occur in highly aerobic cells.
“In contrast, mtDNA disorders typically occur in highly aerobic cells.”
The paper relies on this without support.
S. cerevisiae is currently the only known organism in which mitochondrial genetic transformation is possible.
“Saccharomyces cerevisiae is currently the only known organism in which mitochondrial genetic transformation is possible.”
The paper relies on this without support.
S. cerevisiae can survive in the complete absence of functional mtDNA.
“Furthermore, in view of the ability of S. cerevisiae to survive in the complete absence of functional mtDNA, the study of very severe mitochondrial defects is possible.”
The paper relies on this without support.
Not all human mt-tRNAs share strong homology with yeast mt-tRNAs.
“Not all human mt-tRNAs share strong homology with yeast mt-tRNAs.”
The paper relies on this without support.
Fermentative yeast such as S. cerevisiae lack complex I.
“Finally, fermentative yeast such as S. cerevisiae lack complex I.”
The paper relies on this without support.
It is not possible to directly manipulate the mouse mitochondrial genome.
“As it is not possible to directly manipulate their mitochondrial genome, researchers have been forced to adopt more ingenious and indirect ways of engineering mouse mtDNA.”
The paper relies on this without support.
No effective treatment options are currently available for patients with mitochondrial dysfunction, except in rare cases where surgery or transplant may be indicated.
“Despite considerable advances over the last decade in our understanding of mitochondrial genetics and function and the pathogenesis of mtDNA diseases, no effective treatment options are currently available for patients with mitochondrial dysfunction, except in rare cases where surgery or transplant may be indicated.”
The paper relies on this without support.
Satellite cells proliferate in response to damage caused by concentric or eccentric muscular contractions.
“Undifferentiated myogenic cells, satellite cells, are known to proliferate in response to damage caused by concentric (shortening) or eccentric (lengthening) muscular contractions.”
The paper relies on this without support.
Pathogenic mtDNA mutations invariably result in a general defect in mitochondrial respiration that leads to a reduced ability to produce cellular ATP.
“Pathogenic mtDNA mutations invariably result in a general defect in mitochondrial respiration that leads to a reduced ability to produce cellular ATP.”
The paper relies on this without support.
No effective therapies or cures are presently available for patients with mtDNA disease.
“Disappointingly, no effective therapies or cures are presently available for patients with mtDNA disease.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“More recently, estimates have increased the mutation rate from 10- to 17-fold higher in mtDNA than nuclear genomic (nDNA) (Tuppen et al., 2010).”
From Role of the mitochondrial DNA replication machinery in mitochondrial DNA mutagenesis, aging and age-related diseases (2017) · cites this paper as Tuppen et al., 2010
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
LHON mutation is given in opposite directions
MinorThe LHON section identifies the mutation at position 11778 as G to A, but later in the same paragraph calls it A to G.
“There are three primary LHON mtDNA mutations (m.11778G N A, m.3460G N A, and m.14484T N C)”
“Whilst the majority of patients with m.11778A N G who have symptoms develop LHON”
Figure 1's list of 13 polypeptides omits ND5 and ND6
MinorThe figure caption presents its list as the 13 mtDNA-encoded respiratory-chain polypeptides, but the listed names account for only 11. Elsewhere the paper identifies MT-ND6 as an mtDNA gene, which is absent from that list; it also discusses MT-ND5.
“13 essential RC polypeptides: ND1-ND4 and ND4L, subunits of complex I (green), CYTB, a subunit of complex III (purple), COI-COIII, catalytic subunits of complex IV (yellow), and ATP6 and ATP8, subunits of complex V (blue).”
“Two heteroplasmic point mutations introduced in MT-ND6 (m.13885insC) and MT-CO1 (m.6589T N C) resulted in myopathy and cardiomyopathy [174]”
Citations
Cites
1 retracted
Endurance exercise is protective for mice with mitochondrial myopathy
Wenz, T., Diaz, F., Hernandez, D., & Moraes, C. T. (2009) · Journal of Applied Physiology · doi:10.1152/japplphysiol.91571.2008 · Cited by 78 · cited 1×
“Recently, the bene fi ts of daily aerobic exercise have been further demonstrated in conditional COX10 knockoutmice,whichtypicallydevelopseveremyopathy at ∼ 2.5 – 3 months [231].”
BackgroundInfluentialRetractedSequence and organization of the human mitochondrial genome
Anderson, S., Bankier, A. T., Barrell, B. G., de Bruijn, M. H. L., Coulson, A. R., Drouin, J., Eperon, I. C., Nierlich, D. P., Roe, B. A., Sanger, F., et al. (1981) · Nature · doi:10.1038/290457a0 · Cited by 9,740
Reanalysis and revision of the Cambridge reference sequence for human mitochondrial DNA
Andrews, R. M., Kubacka, I., Chinnery, P. F., Lightowlers, R. N., Turnbull, D. M., & Howell, N. (1999) · Nature Genetics · doi:10.1038/13779 · Cited by 3,337 · cited 1×
“heavy (H) strands), circular genome, the complete sequence of which was fully elucidated in 1981 [11] and further revised in 1999 [12].”
BackgroundSelf-citationPremature ageing in mice expressing defective mitochondrial DNA polymerase
Trifunovic, A., Wredenberg, A., Falkenberg, M., Spelbrink, J. N., Rovio, A. T., Bruder, C. E., Bohlooly-Y, M., Gidlöf, S., Oldfors, A., Wibom, R., et al. (2004) · Nature · doi:10.1038/nature02517 · Cited by 2,734 · cited 1×
“Alternative and more successful approaches to developing mouse models of mitochondrial disease involve manipulating the nuclear genes that regulate mtDNA maintenance and replication, such as TFAM [176 – 182], POLG ( ‘ Mutator ’ model) [183], and PEO1 (Twinkle; ‘ Deletor ’ model) [184].”
BackgroundtRNA punctuation model of RNA processing in human mitochondria
Ojala, D., Montoya, J., & Attardi, G. M. (1981) · Nature · doi:10.1038/290470a0 · Cited by 2,561 · cited 2×
“Mitochondrial translation is characterised by a number of distinct features including RNA-poor mitoribosomes [48], bicistronic transcripts [49], partial stop codons in some of the transcripts that are completed by polyadenylation [31,50], and deviation from the standard genetic code.”
BackgroundMitochondrial DNA mutation associated with Leber’s hereditary optic neuropathy
Wallace, D. C., Singh, G., Lott, M. T., Hodge, J. A., Schurr, T. G., Lezza, A. M. S., Elsas, L. J., & Nikoskelainen, E. K. (1988) · Science · doi:10.1126/science.3201231 · Cited by 2,440 · cited 1×
“The fi rst pathogenic mtDNA mutations were identi fi ed in 1988 [54,55].”
BackgroundGoto, Y.-I., Nonaka, I., & Horai, S. (1990) · Nature · doi:10.1038/348651a0 · Cited by 2,070 · cited 1×
“Over 80% of patients with MELAS have the m.3243A N G mutation in the MT-TL1 gene [109,110].”
BackgroundA Mitochondrial Protein Compendium Elucidates Complex I Disease Biology
Pagliarini, D. J., Calvo, S. E., Chang, B., Sheth, S. A., Vafai, S. B., Ong, S.-E., Walford, G. A., Sugiana, C., Boneh, A., Chen, W. K., et al. (2008) · Cell · doi:10.1016/j.cell.2008.06.016 · Cited by 1,994 · cited 3×
“understanding of the role of mitochondria in health and disease [209,225,226].”
BackgroundMethodInfluentialMitochondrial DNA mutations in human disease
Taylor, R. W., & Turnbull, D. M. (2005) · Nature Reviews Genetics · doi:10.1038/nrg1606 · Cited by 1,922
Self-citationDeletions of muscle mitochondrial DNA in patients with mitochondrial myopathies
Holt, I. J., Harding, A. E., & MORGAN-HUGHES, J. A. (1988) · Nature · doi:10.1038/331717a0 · Cited by 1,860 · cited 2×
“The fi rst pathogenic mtDNA mutations were identi fi ed in 1988 [54,55].”
BackgroundMethod
Flagged first, then by citations
11 of the 272 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- Chen, 1995, Rearranged mitochondrial genomes are present in human oocytes, Am. J. Hum. Genet., 57, 239
- Oefner, 1995, Comparative DNA sequencing by high-performance liquid chromatography, Am. J. Hum. Genet., 57, A266
Cited by
Sorted by citations
Items 201–300 of 681
MT‐CYB mutations in hypertrophic cardiomyopathy
Hagen, C. M., Aidt, F., Havndrup, O., et al. (2013) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.5 · Cited by 34
“Furthermore, mtDNA variants are difficult to interpret because of the extensive sequence variation (Montoya et al. 2009), the complex genotype–phenotype relationship and the difficulty in performing functional analyses on the mutated proteins (Tuppen et al. 2010).”
BackgroundNutritional Interventions for Mitochondrial OXPHOS Deficiencies: Mechanisms and Model Systems
Kuszak, A. J., Espey, M. G., Falk, M. J., Holmbeck, M. A., Manfredi, G., Shadel, G. S., Vernon, H. J., & Zolkipli‐Cunningham, Z. (2017) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-020117-043644 · Cited by 35
DNA Delivery to Mitochondria: Sequence Specificity and Energy Enhancement
Ibrahim, N., Handa, H., Cosset, A., Koulintchenko, M. V., Konstantinov, Y. M., Lightowlers, R. N., Dietrich, A., & Weber‐Lotfi, F. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0516-4 · Cited by 33
“The identification of pathologies caused by mutations in the mitochondrial genome has been constantly increasing during the last decade ( 1 ).”
BackgroundReview: can diet influence the selective advantage of mitochondrial DNA haplotypes?
Ballard, J. W. O., & Youngson, N. A. (2015) · Bioscience Reports · doi:10.1042/bsr20150232 · Cited by 36
Significance of Mitochondria DNA Mutations in Diseases
Zhu, Z., & Wang, X. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-6674-0_15 · Cited by 33
Dynamic of mitochondrial network, cristae, and mitochondrial nucleoids in pancreatic β-cells
Ježek, P., & Dlasková, A. (2019) · Mitochondrion · doi:10.1016/j.mito.2019.06.007 · Cited by 32
Mullane, K., & Williams, M. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.09.027 · Cited by 32
Akhtar, A., Singh, S., Kaushik, R., Awasthi, R., & Behl, T. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102289 · Cited by 38
Soon, B. H., Murad, N. A. A., Then, S., Bakar, A. A., Fadzil, F., Thanabalan, J., Haspani, M. S. M., Jeng, T. C., Tamil, A. M., Harun, R., et al. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00231 · Cited by 35
“The threshold of themutant and wild type may be varies due to different passages in the culture, hence the functional aspects of these mutations is difficult to predict (Tuppen et al., 2010).”
BackgroundPompei, M., & Pompei, F. (2018) · Journal of Assisted Reproduction and Genetics · doi:10.1007/s10815-018-1370-7 · Cited by 32
Sreekumar, P. G., & Kannan, R. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101663 · Cited by 32
“The mitochondrial genome has a very high mutation rate, 10- to 17-fold higher than that observed in nuclear DNA [42].”
BackgroundFang, J., Uchiumi, T., Yagi, M., Matsumoto, S., Amamoto, R., Saito, T., Takazaki, S., Kanki, T., Yamaza, H., Nonaka, K., et al. (2012) · Bioscience Reports · doi:10.1042/bsr20120046 · Cited by 32
Saturation of the Human Phenome
Samuels, M. E. (2010) · Current Genomics · doi:10.2174/138920210793175886 · Cited by 32
“Well documented mutations in mitochondrial genes, including tRNA and rRNA coding genes, lead to clinical disorders of the mitochondrion, which although complex physiologically are generally definable by experienced clinicians [234, 235].”
BackgroundMitochondrial Mutations in Cardiac Disorders
Lee, S. R., & Han, J. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-55330-6_5 · Cited by 33
Sato, Y., Sakurai, Y., Kajimoto, K., Nakamura, T., Yamada, Y., Akita, H., & Harashima, H. (2016) · Macromolecular Bioscience · doi:10.1002/mabi.201600179 · Cited by 32
Fleck, D., Phu, L., Verschueren, E., Hinkle, T. B., Reichelt, M., Bhangale, T., Haley, B., Wang, Y., Graham, R., Kirkpatrick, D. S., et al. (2019) · Journal of Neuroscience · doi:10.1523/jneurosci.0116-19.2019 · Cited by 31
“…genome itself or in genes coding for mitochondrial proteins are associated with neurodegenerative diseases such as Parkinson’s disease, Leigh syndrome, and ataxia-neuropathy syndrome (Mattson et al., 2008; Calvo and Mootha, 2010; Tuppen et al., 2010; Johri and Beal, 2012; Koopman et al., 2013).”
BackgroundMitochondrial Dynamics and Heart Failure
Knowlton, A. A., & Liu, T. (2015) · Comprehensive physiology · doi:10.1002/cphy.c150022 · Cited by 32
MITO-Porter for Mitochondrial Delivery and Mitochondrial Functional Analysis
Yamada, Y., & Harashima, H. (2016) · Handbook of experimental pharmacology · doi:10.1007/164_2016_4 · Cited by 30
Human mitochondrial DNA diseases and Drosophila models
Chen, Z., Zhang, F., & Xu, H. (2019) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2019.03.009 · Cited by 29
Mazzaccara, C., Mirra, B., Barretta, F., Caiazza, M., Lombardo, B., Scudiero, O., Tinto, N., Limongelli, G., & Frisso, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115742 · Cited by 30
Recent advances in mitochondrial diseases: From molecular insights to therapeutic perspectives
Aldossary, A. M., Tawfik, E. A., Alomary, M. N., Alsudir, S. A., Alfahad, A. J., Alshehri, A. A., Almughem, F. A., Mohammed, R. Y., & Alzaydi, M. M. (2022) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2022.05.011 · Cited by 37
Current strategies towards therapeutic manipulation of mtDNA heteroplasmy
Moraes, C. T. (2016) · Frontiers in bioscience · doi:10.2741/4529 · Cited by 31
“When pathogenic mutations occur in the mtDNA most often both mutant and wild-type copies co-exist within the same cell, a phenomenon known as heteroplasmy (5), and, in general, only when the mutation load is higher than approximately 80% symptoms manifest (6).”
BackgroundRomero, E. E., & Hernandez, F. E. (2017) · Physical Chemistry Chemical Physics · doi:10.1039/c7cp05356h · Cited by 29
Manipulation of mitochondrial genes and mtDNA heteroplasmy
Bacman, S. R., Gammage, P. A., Minczuk, M. A., & Moraes, C. T. (2020) · Methods in cell biology · doi:10.1016/bs.mcb.2019.12.004 · Cited by 30
Comparison of whole genome sequencing and targeted sequencing for mitochondrial DNA
Chen, R., Aldred, M. A., Xu, W., Zein, J., Bazeley, P. S., COMHAIR, S. A. A., Meyers, D. A., Bleecker, E. R., Liu, C., ERZURUM, S. C., et al. (2021) · Mitochondrion · doi:10.1016/j.mito.2021.01.006 · Cited by 29
Oliveira, P. H., da Silva, C. L., & Cabral, J. M. S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059907 · Cited by 30
“Rearrangement of mitochondrial DNA (mtDNA) and consequent loss of mitochondrial function has been implicated in the aging process and in a broad range of clinical phenotypes (reviewed in [1]).”
qPCR-based mitochondrial DNA quantification: Influence of template DNA fragmentation on accuracy
Jackson, C. B., Gallati, S., & Schaller, A. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.05.121 · Cited by 29
“heterogeneous disorders characterised by a tissue-specific (or multi-systemic) severe quantitative reduction of mtDNA [5,7–11].”
BackgroundOrganelle trafficking of chimeric ribozymes and genetic manipulation of mitochondria
Val, R., Wyszko, E., Valentin, C., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr580 · Cited by 29
“Mutations in the human organelle genome cause severe neurodegenerative diseases that are currently incurable (10).”
BackgroundShetty, D. K., Kalamkar, K., & Inamdar, M. S. (2018) · Stem Cell Reports · doi:10.1016/j.stemcr.2018.05.015 · Cited by 29
“However, genetic changes that result in perturbed mitochondrial activity often lead to diseases of impaired metabolism or malignancies (Ghezzi et al., 2011; Swalwell et al., 2011; Tuppen et al., 2010).”
BackgroundSpotlight on the relevance of mtDNA in cancer
Cruz‐Bermúdez, A., Vicente-Blanco, R. J., González‐Vioque, E., Provencio, M., Fernández‐Moreno, M. Á., & Garesse, R. (2016) · Clinical & Translational Oncology · doi:10.1007/s12094-016-1561-6 · Cited by 29
Nguyen, H., Zarriello, S., Rajani, M., Tuazon, J. P., Napoli, E., & Borlongan, C. V. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19072127 · Cited by 27
“The symptoms are severe and often fatal in early newborns with hyperlactacidemia, hypertrophic cardiomyopathy, and high levels of 3-methylglutaconic acid [56,57].”
BackgroundCardiac complications in inherited mitochondrial diseases
Behjati, M., Sabri, M. R., Far, M. E., & Nejati, M. (2020) · Heart Failure Reviews · doi:10.1007/s10741-020-10009-1 · Cited by 28
Marmolejo-Garza, A., Medeiros-Furquim, T., Rao, R. G., Eggen, B. J. L., Boddeke, E., & Dolga, A. M. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2022.119326 · Cited by 29
“When tissues accumulate a certain ratio of mutant versus wild-type mtDNA, cells produce less ATP, reactive oxygen species (ROS) levels increase, and apoptotic cell death could occur [17].”
BackgroundGenetics of mitochondrial diseases: Current approaches for the molecular diagnosis
Schlieben, L. D., & Prokisch, H. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-12-821751-1.00011-7 · Cited by 32
Wojewoda, M., Duszyński, J., & Szczepanowska, J. (2010) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2010.01.035 · Cited by 28
Perspectives of mitochondrial medicine
Zorov, D. B., Исаев, Н. К., Plotnikov, E. Y., Silachev, D. N., Zorova, L. D., Pevzner, I. B., Morosanova, M. A., Jankauskas, S. S., Zorov, S. D., & Babenko, V. А. (2013) · Biochemistry (Moscow) · doi:10.1134/s0006297913090034 · Cited by 28
Pathogenic mitochondrial mt-tRNAAla variants are uniquely associated with isolated myopathy
Lehmann, D., Schubert, K., Joshi, P. R., et al. (2015) · European Journal of Human Genetics · doi:10.1038/ejhg.2015.73 · Cited by 27
Self-citationGagliardi, D., Mauri, E., Magri, F., et al. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00038 · Cited by 27
“This disease course probably depends on two aspects: the cells of the organism need higher amounts of energy during childhood due to system development, and an early presentation of symptoms is more often associated with a higher mutation load in the mtDNA (9).”
BackgroundFatima, S., Suhail, N., Alrashed, M., Wasi, S., Aljaser, F. S., AlSubki, R. A., Alsharidah, A. S., & Banu, N. (2021) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.22701 · Cited by 25
Pathophysiology of chronic peripheral ischemia: new perspectives
Signorelli, S. S., Vanella, L., Abraham, N. G., Scuto, S., Marino, E., & Ročić, P. (2020) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622319894466 · Cited by 28
Tomita, K., Kuwahara, Y., Igarashi, K., Roudkenar, M. H., Roushandeh, A. M., Kurimasa, A., & Sato, T. (2021) · Genes · doi:10.3390/genes12091348 · Cited by 29
Elizalde-Velázquez, G. A., Rosas-Ramírez, J. R., Raldúa, D., García-Medina, S., Orozco-Hernández, J. M., Rosales-Pérez, K. E., Islas‐Flores, H., Galar‐Martínez, M., Guzmán-García, X., & Gómez‐Oliván, L. M. (2022) · Chemosphere · doi:10.1016/j.chemosphere.2022.133667 · Cited by 25
Gehrig, S. M., Mihaylova, V., Frese, S., Mueller, S. M., Ligon‐Auer, M., Spengler, C. M., Petersen, J. A., Lundby, C., & Jung, H. H. (2016) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-016-0488-x · Cited by 27
Anatomy, pathophysiology and basic mechanisms of disease
Crawford, J. M., & Burt, A. D. (2011) · Elsevier eBooks · doi:10.1016/b978-0-7020-3398-8.00001-5 · Cited by 32
Vernon, H. J., & Bindoff, L. A. (2018) · Handbook of clinical neurology · doi:10.1016/b978-0-444-64189-2.00009-3 · Cited by 25
Mitochondrial Effects of Plant-Made Compounds
Biasutto, L., Szabó, I., & Zoratti, M. (2011) · Antioxidants and Redox Signaling · doi:10.1089/ars.2011.4021 · Cited by 25
“The origins, transmission, and evolution during life-time of mtDNA alterations constitute a complex research area that cannot be tackled here but is covered by a number of recent reviews ( e.g. , 105, 206, 216).”
Pienaar, I. S., Howell, N., & Elson, J. L. (2017) · Mitochondrion · doi:10.1016/j.mito.2017.04.002 · Cited by 25
Perspective: Computational modeling of accurate cellular membranes with molecular resolution
Klauda, J. B. (2018) · The Journal of Chemical Physics · doi:10.1063/1.5055007 · Cited by 25
Shukla, P., Mukherjee, S., & Patil, A. D. (2020) · DNA and Cell Biology · doi:10.1089/dna.2019.5323 · Cited by 25
“The mitochondrial genome is a small, circular double-stranded DNA molecule of 16,569 nucleotides that encode 37 genes, 13 of which encode core structural respiratory chain complex subunits, 22 encode transfer RNAs, and 2 encode ribosomal RNAs (Tuppen et al., 2010).”
BackgroundSchaller, A., Desetty, R. D., Hahn, D., et al. (2011) · Mitochondrion · doi:10.1016/j.mito.2011.01.005 · Cited by 24
“POLG, POLG2, Twinkle and ANT1) is unlikely (Spinazzola and Zeviani, 2009; Tuppen et al., 2010).”
Gürses, C., Azaklı, H., Alptekin, A., Çakiris, A., Abacı, N., Arıkan, M., Kurşun, O., Gökyiğit, A., & Üstek, D. (2014) · Gene · doi:10.1016/j.gene.2014.01.030 · Cited by 24
“Although the role of mitochondrial DNA (mtDNA) abnormalities in a diverse range of diseases has been identified in the last decades, many mechanisms of human mitochondrial genetics still need to be clarified (Tuppen et al., 2010).”
BackgroundAlpha lipoic acid and vitamin E improve atorvastatin-induced mitochondrial dysfunctions in rats
Faki, H. E., Traş, B., & Üney, K. (2020) · Mitochondrion · doi:10.1016/j.mito.2020.02.011 · Cited by 25
Guja, K. E., Venkataraman, K., Yakubovskaya, E., Shi, H., Mejía, E., Hambardjieva, E., Karzai, A. W., & García–Díaz, M. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt547 · Cited by 24
Beyond Death: Unmasking the Intricacies of Apoptosis Escape
Ergün, S., Aslan, S., Yeşilyurt, D. D., Kayaoğlu, S., Saydam, M., Keleş, Y., kolcuoğlu, D., Hekim, N., & Gunes, S. O. (2024) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-024-00718-w · Cited by 26
“Mutations in mtDNA, therefore, are crucial, particularly in terms of the enzymes and proteins required for oxidative phosphorylation, as they can lead to mitochondrial dysfunction and inefficient ATP production [44].”
BackgroundNorota, K., Ishizuka, S., Hirose, M., Sato, Y., Maeki, M., Tokeshi, M., Ibrahim, S. M., Harashima, H., & Yamada, Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-03671-8 · Cited by 25
Tharayil, S. P., & Shukla, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136233 · Cited by 29
Mitochondrial haplogroups and cognitive progression in Parkinson’s disease
Liu, G., Ni, C., Zhan, J., Li, W., Luo, J., Liao, Z., Locascio, J. J., Xian, W., Chen, L., Pei, Z., et al. (2022) · Brain · doi:10.1093/brain/awac327 · Cited by 26
Venter, M., Malan, L., van Dyk, E., Elson, J. L., & van der Westhuizen, F. H. (2016) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2016.12.003 · Cited by 23
What Can Stem Cell Models Tell Us About Human Germ Cell Biology?
Irie, N., Sybirna, A., & Surani, M. A. (2018) · Current Topics in Developmental Biology · doi:10.1016/bs.ctdb.2018.02.010 · Cited by 22
DNA repair pathways in the mitochondria
King, D. E., & Copeland, W. C. (2025) · DNA repair · doi:10.1016/j.dnarep.2025.103814 · Cited by 22
Clinically proven mtDNA mutations are not common in those with chronic fatigue syndrome
Schoeman, E. M., van der Westhuizen, F. H., Erasmus, E., van Dyk, E., Knowles, C. V. Y., Al-Ali, S., Ng, W., Taylor, R. W., Newton, J. L., & Elson, J. L. (2017) · BMC Medical Genetics · doi:10.1186/s12881-017-0387-6 · Cited by 22
“However, given the high levels of heteroplasmy required to see a biochemical defect in mitochondrial patients [9] it becomes biologically less plausible that very low levels of mtDNA mutations would be exerting a phenotypic effect even in the context of co-occurrence with a disease phenotype such as CFS.”
BackgroundSelf-citationGuo, H., Zhuang, X., Zhang, A., Zhang, W., Yuan, Y., Guo, L., Yu, D., Liu, J., Yang, D.-K., & Yao, Y. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.06.010 · Cited by 22
A human pathology-related mutation prevents import of an aminoacyl-tRNA synthetase into mitochondria
Messmer, M., Florentz, C., Schwenzer, H., Scheper, G. C., van der Knaap, M. S., Maréchal‐Drouard, L., & Sissler, M. (2011) · Biochemical Journal · doi:10.1042/bj20101902 · Cited by 25
Synergistic Effects of the in cis T251I and P587L Mitochondrial DNA Polymerase γ Disease Mutations
DeBalsi, K. L., Longley, M. J., Hoff, K. E., & Copeland, W. C. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.773341 · Cited by 22
Liu, C., Fetterman, J. L., Liu, P., Luo, Y., Larson, M. G., Vasan, R. S., Zhu, J., & Levy, D. A. (2018) · Human Genetics · doi:10.1007/s00439-018-1873-4 · Cited by 22
“Accumulating evidence has also suggested that mtDNA mutations are involved in age-related common diseases such as cardiovascular disease and cancers (Wallace 2005; Tuppen et al. 2010; Taylor and Turnbull 2005; Seyfried 2015; Seyfried et al. 2015; Saxena et al. 2006; Liu et al. 2012; Byrne et al. 2009; Kang et al. 2016…”
Horibe, S., Ishikawa, K., Nakada, K., Wake, M., Takeda, N., Tanaka, T., Kawauchi, S., Sasaki, N., & Rikitake, Y. (2021) · Oncology Reports · doi:10.3892/or.2021.8243 · Cited by 22
“Numerous mtDNA mutations have been identified in the development and progression of various pathologies and mitochondrial dysfunction is implicated in various human diseases, including diabetes, Alzheimer's disease, and cancer (10).”
BackgroundChan, F., Lax, N. Z., Davies, C. H., Turnbull, D. M., & Cunningham, M. O. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.10.033 · Cited by 21
“This mtDNA contains just 37 genes in humans and is strictly derived through maternal inheritance (Tuppen et al., 2010).”
Self-citationHu, Z., Zhao, Z., Wu, Z., et al. (2011) · Mitochondrion · doi:10.1016/j.mito.2011.05.012 · Cited by 21
Devall, M. A. M., Burrage, J., Caswell, R. C., Johnson, M. B., Troakes, C., Al‐Sarraj, S., Jeffries, A. R., Mill, J. S., & Lunnon, K. (2015) · BioTechniques · doi:10.2144/000114343 · Cited by 21
Mitochondrial Genetic Variation in Iranian Infertile Men with Varicocele.
Heidari, M., Khatami, M., Danafar, A., Dianat, T., Farahmand, G., & Talebi, A. R. (2016) · PubMed Central · doi:10.22074/ijfs.2016.5047 · Cited by 21
“The OXPHOS machinery is made up of over 80 different polypeptides, of which the mtDNA encodes 13 polypeptides including complex I, III, IV and V subunits (17).”
BackgroundQueen, R. A., Steyn, J. S., Lord, P., & Elson, J. L. (2017) · PLoS ONE · doi:10.1371/journal.pone.0187862 · Cited by 21
“Within a single cell, mtDNA copies may all be same (homoplasmic) or different (heteroplasmic) [1].”
BackgroundInfluentialDhiman, H., Gerstl, M. P., Ruckerbauer, D. E., Hanscho, M., Himmelbauer, H., Clarke, C., Barron, N., Zanghellini, J., & Borth, N. (2019) · Biotechnology Journal · doi:10.1002/biot.201800681 · Cited by 22
Martinez, C. S., Zheng, A., & Xiao, Q. (2024) · Antioxidants · doi:10.3390/antiox13111330 · Cited by 26
Steffann, J., Monnot, S., Magen, M., Assouline, Z., Gigarel, N., Ville, Y. G., Salomon, L. J., Bessière, B., Martinovic, J., Rötig, A., et al. (2020) · Genetics in Medicine · doi:10.1038/s41436-020-01043-3 · Cited by 20
Mitochondrial protein synthesis and the bioenergetic cost of neurodevelopment
Bülow, P., Patgiri, A., & Faúndez, V. (2022) · iScience · doi:10.1016/j.isci.2022.104920 · Cited by 18
Mitochondrial donation: A boon or curse for the treatment of incurable mitochondrial diseases
Mani, S., Saxena, N., Taneja, N., & Shome, P. (2018) · Journal of Human Reproductive Sciences · doi:10.4103/jhrs.jhrs_54_17 · Cited by 20
“As per studies, exercise can be used to improve the quality of life of the patients suffering from mitochondrial disease only but cannot treat the disease completely.[1,6,9,10]”
BackgroundThe aetiology of cardiovascular disease: a role for mitochondrial DNA?
Venter, M., van der Westhuizen, F. H., & Elson, J. L. (2018) · Cardiovascular journal of South Africa/Cardiovascular journal of Southern Africa · doi:10.5830/cvja-2017-037 · Cited by 20
“mtDNA is maternally inherited and has a much higher mutation rate than nDNA, possibly 10 to 17 times higher.(14) Maternal inheritance results in a lack of bi-parental recombination and therefore the evolution of mtDNA is defined by the emergence of distinct lineages called haplogroups.”
BackgroundThe Role of Mitochondrial DNA Variation in Drug Response: A Systematic Review
Jones, S. W., Ball, A. L., Chadwick, A. E., & Alfirevic, A. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.698825 · Cited by 18
“Therefore, propagation of bioenergetic defects requires a minimum critical ratio of mutant to wild-type mtDNA to be met, typically in the range of 60–90% (Tuppen et al., 2010).”
BackgroundMitochondrial translational inhibitors in the pharmacopeia
Cohen, B. H., & Saneto, R. P. (2012) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2012.02.023 · Cited by 20
Ardissone, A., Invernizzi, F., Nasca, A., Moroni, I., Farina, L., & Ghezzi, D. (2015) · Molecular Genetics and Metabolism Reports · doi:10.1016/j.ymgmr.2015.10.006 · Cited by 20
“In addition, although common for heteroplasmic mutations in mitochondrial DNA, incomplete penetrance has been described also for diverse homoplasmic mutations causing even severe infantile mitochondrial diseases [12,13].”
BackgroundSouren, N. Y., Gerdes, L. A., Kümpfel, T., Lutsik, P., Klopstock, T., Hohlfeld, R., & Walter, J. (2016) · Human Mutation · doi:10.1002/humu.23003 · Cited by 20
“To be considered pathogenic, the mutation load should exceed a certain threshold, which is mutation and tissue dependent [Tuppen et al., 2010].”
BackgroundMatkarimov, B. T., & Saparbaev, M. K. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-41283-8_6 · Cited by 18
Trends in Mitochondrial Therapeutics for Neurological Disease
Leitão-Rocha, A., Guedes-Dias, P., Pinho, B. R., & Oliveira, J. M. A. (2015) · Current Medicinal Chemistry · doi:10.2174/0929867322666150209160317 · Cited by 19
O’Farrell, N. J., Feighery, R., Picardo, S. L., Lynam‐Lennon, N., Biniecka, M., McGarrigle, S. A., Phelan, J. J., MacCarthy, F., O’Toole, D., Fox, E., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2544-2 · Cited by 19
“In our study, using the RMC assay, mitochondrial deletions, a form of rearrangement of the mitochondrial genome and a recognized marker of mitochondrial instability [29], were significantly increased in SIM compared with HGD/ EAC.”
MethodStructure, Function, and Responses to Injury
Crawford, J. M., Bioulac‐Sage, P., & Hytiroglou, P. (2017) · Elsevier eBooks · doi:10.1016/b978-0-7020-6697-9.00001-7 · Cited by 28
High-resolution melting analysis of 15 genes in 60 patients with cytochrome-c oxidase deficiency
Vondráčková, A., Veselá, K., Hansíková, H., et al. (2012) · Journal of Human Genetics · doi:10.1038/jhg.2012.49 · Cited by 19
Mitochondrial proteotoxicity: implications and ubiquitin-dependent quality control mechanisms
Karbowski, M., Oshima, Y., & Verhoeven, N. A. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04604-8 · Cited by 21
“The matrix also contains the mitochondrial DNA (mtDNA), which in humans encode for 13 proteins belonging to the OXPHOS complexes, and cofactors, such as tRNAs and rRNA necessary for mitochondrial protein translation [12]”
BackgroundThe Interplay between Dysregulated Metabolism and Epigenetics in Cancer
Bassal, M. A. (2023) · Biomolecules · doi:10.3390/biom13060944 · Cited by 19
Anders, A. G., Tidwell, E. D., Gadkari, V. V., Koutmos, M., & Ruotolo, B. T. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.3c09230 · Cited by 19
Mitochondria in biology and medicine – 2023
Disha, B., Mathew, R. P., Dalal, A. B., Mahato, A. K., Satyamoorthy, K., Singh, K. K., Kumarasamy Thangaraj, K., & Govindaraj, P. (2024) · Mitochondrion · doi:10.1016/j.mito.2024.101853 · Cited by 20
Das, M., Sarma, B. P., Ahmed, G., Nirmala, C., & Choudhury, M. K. (2012) · Free Radicals and Antioxidants · doi:10.5530/ax.2012.2.2.6 · Cited by 18
Sample adequacy controls for infectious disease diagnosis by oral swabbing
Deviaene, M., Weigel, K. M., Wood, R. C., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0241542 · Cited by 18
“MtDNA is suitable for use as SACs in infectious disease diagnostic tests as they are always present in detectable quantities, and polymorphisms within these genes are rare and mitigated by the heteroplasmy of mtDNA [22,23].”
Neuroimaging of Mitochondrial Cytopathies
Alves, C., Gonçalves, F. G., Grieb, D., Lucato, L. T., Goldstein, A. C., & Zuccoli, G. (2018) · Topics in Magnetic Resonance Imaging · doi:10.1097/rmr.0000000000000173 · Cited by 19
Roles of the mitochondrial replisome in mitochondrial DNA deletion formation
Oliveira, M. T., Pontes, C. D. B., & Ciesielski, G. L. (2020) · Genetics and Molecular Biology · doi:10.1590/1678-4685-gmb-2019-0069 · Cited by 18
“, replication-slippage would account for the class I deletions, whereas DSB repair would lead to classes II and III, or, alternatively, that replication-slippage may be specific to sporadic deletions, and DSB repair to the secondary deletions (Degoul et al., 1991; Mita et al., 1990; Wanrooij et al., 2004; Tuppen et al…”
BackgroundMartino, C. D., & Pallotta, M. L. (2011) · Planta · doi:10.1007/s00425-011-1428-6 · Cited by 18
“Aging is characterized by a progressive deterioration of physiological functions and metabolic processes (Palla `s et al. 2008; Huang et al. 2010) and the process of aging correlates with a loss of antioxidant capacity and consequently with an increase in ROS ( Tuppen et al. 2010 ).”
BackgroundZamzami, M. A., Duley, J. A., Price, G. R., Venter, D. J., Yarham, J. W., Taylor, R. W., Catley, L. P., Florin, T. H., Marinaki, A. M., & Bowling, F. G. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-24 · Cited by 18
“The high mutation rate associated with mtDNA is thought to be the result of inappropriate incorporation of rogue nucleotides into the mtDNA [15] which may be caused by: (a) exposure to high concentrations of reactive oxygen species (ROS) generated in the mitochondria from the electron transfer system [16], or (b) lack…”
BackgroundSelf-citationFoury, F., & Szczepanowska, K. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027847 · Cited by 18
“More than one hundred pathogenic mutations have been identified in the mitochondrial genome with a prevalence of at least 1 in 10 000 adult people [1].”
Mitochondrial DNA in Human Diversity and Health: From the Golden Age to the Omics Era
Hernández, C. L. (2023) · Genes · doi:10.3390/genes14081534 · Cited by 21
“In this context, there are several features of mtDNA—as a consequence of the organellar location and heteroplasmy—that must be considered: (i) Threshold effect: A certain proportion of mutated DNA, with respect to normal mtDNA, is required for the dysfunction to become evident; (ii) mitochondrial bottleneck: this phen…”
BackgroundHipps, D., Dobson, P. F., Warren, C., McDonald, D., Fuller, A., Filby, A. J., Bulmer, D., Laude, A., Russell, O. M., Deehan, D. J., et al. (2022) · Bone · doi:10.1016/j.bone.2022.116371 · Cited by 17
Self-citationDar, G. M., Ahmad, E., Ali, A., Mahajan, B., Ashraf, G. M., & Saluja, S. S. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101906 · Cited by 17
Metadata
- Authors
- Tuppen, H. A. L., Blakely, E. L., Turnbull, D. M., & Taylor, R. W.
- Affiliations
- Newcastle University (GB)
- Corresponding author
- Taylor, Robert W.
- Venue
- Biochimica et Biophysica Acta (BBA) - Bioenergetics
- Publisher
- Elsevier BV
- Published
- 2010-02
- Volume
- 1797
- Issue
- 2
- Pages
- 113-128
- ISSN
- 0005-2728 (ISSN-L)
- OpenAlex
- W1997422422
- Semantic Scholar
- b52cea89f7d29e4137fb6e7175963cf0d992f736
- Cited by
- 676
- References
- 272
- Citations by year
- 2026: 19 · 2025: 34 · 2024: 41 · 2023: 32 · 2022: 35 · 2021: 50 · 2020: 51 · 2019: 46 · 2018: 81 · 2017: 44 · 2016: 49 · 2015: 32 · 2014: 24 · 2013: 33 · 2012: 38
- FWCI
- 2.63
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Biochimica et Biophysica Acta (BBA) - Bioenergetics (publishedVersion)
- PubMed (publishedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- Wellcome Trust (074454)
- Sparks
- Muscular Dystrophy UK
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
- Keywords
- mitochondrial DNA mutations, mitochondrial disease, oxidative phosphorylation defects, mitochondrial genetics, nuclear-encoded mitochondrial proteins, mitochondrial disease diagnosis, mitochondrial disease therapy, disease models
- MeSH terms
- DNA, Mitochondrial, Humans, Mutation, Mitochondrial Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review